The potential for uncontrolled generic switching of immunosuppressant transplant drugs, such as tacrolimus or cyclosporine, due to mandatory generic substitution plans, can negatively impact patient (plan member) safety and health outcomes, resulting in higher costs. Does your drug benefit plan have proper safeguards to avoid this scenario?
 |
|
The Bank of Canada is facing an increasingly uncertain 2026 despite experts agreeing on its current policy path. Etienne Bordeleau-Labrecque, vice-president and portfolio manager at...
Running for 20 years, Benefits Canada’s 2025 Face to Face Drug Plan Management Forum is the industry’s most popular drug benefits conference. This year, attendees...
As Canada navigates the evolving drug coverage landscape, private drug plans remain a cornerstone of access, innovation and economic growth. Indeed, private drug plans are...
As dermatological treatments move up the ranking of conditions with the highest paid drug claims, they’ve become increasingly significant for private drug plan sponsors, according...
With the 2026 Winter Olympic Games in full swing, Fidelity Canada is encouraging a sense of community and national pride among employees by celebrating Team...
With global trade wars, environmental, social, and governance pushback and artificial intelligence advances, 2025 was a roller-coaster year for institutional investors. Unfortunately, 2026 is shaping...
It took Peter Deitz eight years to figure out the best way to sell his business. But it wasn’t until the federal government opened up...
A smooth return to office begins with clarity around the purpose of time in the office, as well as meaningful leadership presence, says Courtney Elling,...
